CÁNCER HEREDITARIO DE TIROIDES, SÍNDROMES ASOCIADOS Y ESTUDIO GENÉTICO

Pacini, 2012, Approach to and Treatment of Differentiated Thyroid Carcinoma, Med Clin N Am, 96, 369, 10.1016/j.mcna.2012.01.002 Metzger, 2014, Inherited cancer syndromes and the thyroid: an update, Curr Opin Oncol., 26, 51, 10.1097/CCO.0000000000000030 Wohllk, 1996, Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma, J Clin Endocrinol Metab., 81, 3740 Wells, 2015, Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma, Thyroid., 25, 567, 10.1089/thy.2014.0335 Kebebew, 2000, Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems, Cancer, 88, 1139, 10.1002/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z Díaz, 2012, Multiple endocrine neoplasia: the Chilean experience, Clinics, 67, 7, 10.6061/clinics/2012(Sup01)03 Takahashi, 1995, Oncogenic activation of the ret protooncogene in thyroid cancer, Crit Rev Oncog., 6, 35, 10.1615/CritRevOncog.v6.i1.30 Margraf, 2009, Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations, Hum Mutat, 30, 548, 10.1002/humu.20928 Smith, 2016, Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression, Hum Mol Genet, 25, 1836, 10.1093/hmg/ddw057 Wang, 2015, Familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis, European Journal of Endocrinology., 172, R253, 10.1530/EJE-14-0960 Cetta, 2000, Germline mutations of the APC gene in patients with FAP associated thyroid carcinoma. Results from a European cooperative study, J Clin Endocrinol Metab, 85, 286 Claes, 2011, The genetics of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP), Acta Gastroenterol Belg., 74, 421 Richards, 2010, Familial syndromes associated with thyroid cancer in the era of personalized medicine, Thyroid., 20, 707, 10.1089/thy.2010.1641 Cao, 2016, Clinicopathological features and prognosis of fPTC-a large scale, matched, case-control study, Clin. Endo- crinol., 84, 598, 10.1111/cen.12859 Gara, 2015, Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer, N Engl J Med, 373, 448, 10.1056/NEJMoa1502449 Vriens, 2009, Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer, Thyroid, 19, 1343, 10.1089/thy.2009.1607 Cantara, 2012, Telomere Abnormalities and Chromosome Fragility in Patients Affected by Familial Papillary Thyroid Cancer, J Clin Endocrinol Metab, 97, E1327, 10.1210/jc.2011-2096 Cantara, 2017, HABP2 G534E variation in familial non-medullary thyroid cancer: an Italian series J Endocrinol Invest., 40, 557 HABP2 Mutation and Nonmedullary Thyroid Cancer. Correspondence To the Editor.N Engl J Med 373;21:2084-86. Kowalik, 2017, The p.G534E variant of HABP2 is not associated with sporadic papillary thyroid carcinoma in a Polish population, Oncotarget., 10.18632/oncotarget.16870 De Mello, 2017, The G534E variant in HABP2 is not associated with increased risk of familial nonmedullary thyroid cancer in Brazilian Kindreds, Clin Endocrinol (Oxf)., 10.1111/cen.13352 Siołek, 2015, CHEK2 mutations and the risk of papillary thyroid cancer, Int J Cancer., 137, 548, 10.1002/ijc.29426